Global Market Access

Navigating Global Healthcare Markets with Syenza’s Expertise

Access Beyond Borders

We're inspired by dynamic and diverse global healthcare markets. As a leading value science company, Syenza supports market access activities with global intelligence and local understanding of pricing, reimbursement, and patients. Our philosophy is to drive efficiences through early engagement with payors and decision-makers to increase the probability of success.

GLOBAL MARKET ACCESS

Global Market Access Strategy

Syenza enables clients to execute on opportunities by evaluating the market access landscape, analysing current payor reimbursement policies, generating pricing insights, developing an optimized market access strategy, and deploying evidence to support access to innovations.

Outsourced Global Market Access

Syenza provides an Embedded Market Access Team (EMAT) where our interdisciplinary professionals boost capacity with rapid evidence reviews, localized cost breakdowns, stakeholder outreach, training, and market/ competitor scanning.

Value-based Contracting

Syenza scenario builds different approaches to value-based contracting based on demonstrable real-world evidence of the clinical and economic value. Our in-market insights and relationships add depth and nuance to each scenario and improves overall decision-making.

Service Outcomes

Clients receive actionable insights
in Market Access Landscape Reports, Comparative Pricing Reports, and Value-Positioning Workshops.

Clients fill capacity gaps in market access organizations with EMAT to enhance launch and post-launch activities.

Clients apply in-market insights to develop value-based contracts that support access to innovations in different markets.

View Our Recent Case Study

Biopharmaceutical Market Access Analysis in Dubai

August 23, 2022

Objective : A market access landscape analysis is the first step to improving access in the target countries. This involved identifying the unmet need in the disease area, audiences with which to build a shared agenda, and shaping national reimbursem

Read More

VIEW ALL

View Our Recent Articles

RSS Healthcare access – Syenza News
  • EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility January 20, 2026
    Curious how 2025’s EMA decisions will change the healthcare landscape? 🔬 The EMA recommended 104 medicines—including 38 new active substances, a record 41 biosimilars, and 16 orphan drugs—while expanding global reach through EU‑M4All, signaling major shifts in access, safety monitoring, and cost dynamics. These trends matter for HEOR, pricing and reimbursement strategies as biosimilars ease […]
    HEOR Staff Writer
  • Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays January 13, 2026
    💰 How is Portugal navigating the complexities of Epidyolex spending amid reimbursement delays? Portugal's National Health Service has spent over €3 million on the CBD-based epilepsy treatment Epidyolex since 2021, revealing crucial insights into patient access and healthcare costs. This article unpacks the implications for rare epilepsy patients and highlights the challenges facing healthcare allocation […]
    HEOR Staff Writer
  • Driving Economic Transformation through Brain Health Investment in Africa January 9, 2026
    🧠 Is Africa ready to invest in its brain health for economic transformation? The Johannesburg Communiqué emphasizes that prioritizing brain health is essential for the continent's growth as it gears up for a workforce boom. With strategies to integrate brain health into primary care and leverage digital innovations, Africa has an opportunity to mitigate costs […]
    João L. Carapinha
VIEW ALL